Logo image of BRZE

BRAZE INC-A (BRZE) Stock Fundamental Analysis

NASDAQ:BRZE - US10576N1028 - Common Stock

31.42 USD
+3.76 (+13.59%)
Last: 9/5/2025, 8:00:35 PM
31.05 USD
-0.37 (-1.18%)
After Hours: 9/5/2025, 8:00:35 PM
Fundamental Rating

4

Overall BRZE gets a fundamental rating of 4 out of 10. We evaluated BRZE against 280 industry peers in the Software industry. While BRZE has a great health rating, there are worries on its profitability. BRZE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BRZE had positive earnings in the past year.
BRZE had a positive operating cash flow in the past year.
In the past 5 years BRZE always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: BRZE reported negative operating cash flow in multiple years.
BRZE Yearly Net Income VS EBIT VS OCF VS FCFBRZE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

With a Return On Assets value of -11.68%, BRZE is not doing good in the industry: 65.71% of the companies in the same industry are doing better.
BRZE's Return On Equity of -21.90% is in line compared to the rest of the industry. BRZE outperforms 41.07% of its industry peers.
Industry RankSector Rank
ROA -11.68%
ROE -21.9%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-15.52%
ROE(3y)-27.38%
ROE(5y)-29.17%
ROIC(3y)N/A
ROIC(5y)N/A
BRZE Yearly ROA, ROE, ROICBRZE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40

1.3 Margins

BRZE has a Gross Margin of 69.44%. This is comparable to the rest of the industry: BRZE outperforms 51.79% of its industry peers.
In the last couple of years the Gross Margin of BRZE has grown nicely.
BRZE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.04%
GM growth 5Y1.88%
BRZE Yearly Profit, Operating, Gross MarginsBRZE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

7

2. Health

2.1 Basic Checks

BRZE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BRZE has been increased compared to 1 year ago.
The number of shares outstanding for BRZE has been increased compared to 5 years ago.
There is no outstanding debt for BRZE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BRZE Yearly Shares OutstandingBRZE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
BRZE Yearly Total Debt VS Total AssetsBRZE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 3.96 indicates that BRZE is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.96, BRZE is in the better half of the industry, outperforming 66.79% of the companies in the same industry.
There is no outstanding debt for BRZE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.96
ROIC/WACCN/A
WACC11.12%
BRZE Yearly LT Debt VS Equity VS FCFBRZE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M 500M

2.3 Liquidity

BRZE has a Current Ratio of 1.92. This is a normal value and indicates that BRZE is financially healthy and should not expect problems in meeting its short term obligations.
BRZE has a Current ratio (1.92) which is in line with its industry peers.
A Quick Ratio of 1.92 indicates that BRZE should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.92, BRZE is in the better half of the industry, outperforming 60.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
BRZE Yearly Current Assets VS Current LiabilitesBRZE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 820.00% over the past year.
Looking at the last year, BRZE shows a very strong growth in Revenue. The Revenue has grown by 25.78%.
BRZE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 43.83% yearly.
EPS 1Y (TTM)820%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)25.78%
Revenue growth 3Y35.6%
Revenue growth 5Y43.83%
Sales Q2Q%23.79%

3.2 Future

The Earnings Per Share is expected to grow by 55.41% on average over the next years. This is a very strong growth
BRZE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.40% yearly.
EPS Next Y-2.8%
EPS Next 2Y43.58%
EPS Next 3Y60.07%
EPS Next 5Y55.41%
Revenue Next Year19.51%
Revenue Next 2Y18.22%
Revenue Next 3Y18.52%
Revenue Next 5Y17.4%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BRZE Yearly Revenue VS EstimatesBRZE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
BRZE Yearly EPS VS EstimatesBRZE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 87.28, the valuation of BRZE can be described as expensive.
The rest of the industry has a similar Price/Earnings ratio as BRZE.
When comparing the Price/Earnings ratio of BRZE to the average of the S&P500 Index (27.06), we can say BRZE is valued expensively.
BRZE is valuated quite expensively with a Price/Forward Earnings ratio of 84.68.
BRZE's Price/Forward Earnings ratio is in line with the industry average.
BRZE is valuated expensively when we compare the Price/Forward Earnings ratio to 22.69, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 87.28
Fwd PE 84.68
BRZE Price Earnings VS Forward Price EarningsBRZE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of BRZE is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 106.82
EV/EBITDA N/A
BRZE Per share dataBRZE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

A more expensive valuation may be justified as BRZE's earnings are expected to grow with 60.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.58%
EPS Next 3Y60.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BRZE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRAZE INC-A

NASDAQ:BRZE (9/5/2025, 8:00:35 PM)

After market: 31.05 -0.37 (-1.18%)

31.42

+3.76 (+13.59%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)09-04 2025-09-04/amc
Earnings (Next)12-15 2025-12-15/amc
Inst Owners77.86%
Inst Owner Change-0.16%
Ins Owners3.49%
Ins Owner Change7.24%
Market Cap3.32B
Analysts84.8
Price Target44.82 (42.65%)
Short Float %6.92%
Short Ratio3.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)87.99%
Min EPS beat(2)50.17%
Max EPS beat(2)125.81%
EPS beat(4)4
Avg EPS beat(4)268.44%
Min EPS beat(4)50.17%
Max EPS beat(4)523.5%
EPS beat(8)8
Avg EPS beat(8)159.72%
EPS beat(12)12
Avg EPS beat(12)115.87%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.56%
Min Revenue beat(2)0.14%
Max Revenue beat(2)0.98%
Revenue beat(4)4
Avg Revenue beat(4)0.67%
Min Revenue beat(4)0.14%
Max Revenue beat(4)0.98%
Revenue beat(8)8
Avg Revenue beat(8)1.73%
Revenue beat(12)12
Avg Revenue beat(12)1.72%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.05%
PT rev (3m)-14.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-65.75%
EPS NY rev (1m)-0.91%
EPS NY rev (3m)-49.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.87%
Valuation
Industry RankSector Rank
PE 87.28
Fwd PE 84.68
P/S 5.35
P/FCF 106.82
P/OCF 80.1
P/B 6.99
P/tB 7.49
EV/EBITDA N/A
EPS(TTM)0.36
EY1.15%
EPS(NY)0.37
Fwd EY1.18%
FCF(TTM)0.29
FCFY0.94%
OCF(TTM)0.39
OCFY1.25%
SpS5.87
BVpS4.49
TBVpS4.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.68%
ROE -21.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.44%
FCFM 5.01%
ROA(3y)-15.85%
ROA(5y)-15.52%
ROE(3y)-27.38%
ROE(5y)-29.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.04%
GM growth 5Y1.88%
F-Score6
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 97.84%
Cap/Sales 1.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z 3.96
F-Score6
WACC11.12%
ROIC/WACCN/A
Cap/Depr(3y)240.58%
Cap/Depr(5y)230.69%
Cap/Sales(3y)3.47%
Cap/Sales(5y)3.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)820%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-2.8%
EPS Next 2Y43.58%
EPS Next 3Y60.07%
EPS Next 5Y55.41%
Revenue 1Y (TTM)25.78%
Revenue growth 3Y35.6%
Revenue growth 5Y43.83%
Sales Q2Q%23.79%
Revenue Next Year19.51%
Revenue Next 2Y18.22%
Revenue Next 3Y18.52%
Revenue Next 5Y17.4%
EBIT growth 1Y21.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year462.67%
EBIT Next 3Y181.62%
EBIT Next 5Y120.88%
FCF growth 1Y194.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y334.33%
OCF growth 3YN/A
OCF growth 5YN/A